The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear¥85.12Fair value¥368.45Bull¥642.40
FairClose
52-week traded range
52W low ¥414.0052W high ¥486.00
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading above the consensus fair value
DAIKEN MEDICAL CO.,LTD. closed at ¥424.00, 15.1% above the consensus fair value of ¥368.45 drawn from 9 valuation models.
Financial DNA score 66/100 — Strong. P/E of 13.2x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
¥115.15
-72.8%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=2.7%, r=10%, tg=3%, n=10yr
Graham Number
¥441.79
+4.2%
√(22.5 × EPS × BVPS)
EPS=32.12, BVPS=270.06
P/E Fair Value
¥642.40
+51.5%
EPS × 20x (sector P/E)
EPS=32.12, Sector P/E=20x
Peter Lynch (PEG)
¥85.12
-79.9%
EPS × Growth% (PEG = 1 is fair)
EPS=32.12, g=2.7%
EV/EBITDA
¥544.17
+28.3%
(EBITDA × 11.3x − Net Debt) ÷ Shares
EBITDA=1.54B
Dividend Discount (DDM)
¥279.50
-34.1%
D1 ÷ (r − g) where D1 = D0×(1+g)
D0=20.01, r=10%, g=2.7%
Book Value (P/B)
¥351.08
-17.2%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=270.06, ROE=12.1%, g=3%, r=10%
Reverse DCF
¥424.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 1.5% | Historical: 2.7%
Margin of Safety
¥299.84
-29.3%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=399.78, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.